NewEdge Advisors’s Organon & Co OGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$16.9K Sell
1,249
-1,033
-45% -$12.4K ﹤0.01% 3406
2026
Q1
$13.7K Sell
2,282
-5
-0.2% -$38 ﹤0.01% 3315
2025
Q4
$16.4K Buy
2,287
+1,209
+112% +$9.55K ﹤0.01% 3314
2025
Q3
$11.5K Sell
1,078
-263
-20% -$2.58K ﹤0.01% 3297
2025
Q2
$13K Sell
1,341
-138
-9% -$1.42K ﹤0.01% 3104
2025
Q1
$22K Sell
1,479
-58
-4% -$892 ﹤0.01% 2830
2024
Q4
$22.9K Sell
1,537
-33
-2% -$538 ﹤0.01% 2775
2024
Q3
$30K Buy
1,570
+18
+1% +$373 ﹤0.01% 2595
2024
Q2
$32.1K Sell
1,552
-34
-2% -$676 ﹤0.01% 2480
2024
Q1
$29.8K Sell
1,586
-155
-9% -$2.66K ﹤0.01% 2480
2023
Q4
$25.1K Sell
1,741
-499
-22% -$6.79K ﹤0.01% 2488
2023
Q3
$38.9K Buy
2,240
+532
+31% +$11.1K ﹤0.01% 2171
2023
Q2
$35.5K Sell
1,708
-179
-9% -$3.89K ﹤0.01% 2204
2023
Q1
$44.4K Sell
1,887
-2,817
-60% -$75.6K ﹤0.01% 2048
2022
Q4
$72K Buy
+4,704
New +$120K ﹤0.01% 1579
2022
Q1
Sell
-20,612
Closed -$628K 1476
2021
Q4
$628K Buy
+20,612
New +$671K 0.01% 965

Other funds holding OGN

NewEdge Advisors's OGN Position: Q2 2026 in Review

NewEdge Advisors reduced its Organon & Co (OGN) stake by 45% in Q2 2026, selling an estimated $12.4K and leaving 1,249 shares worth $16.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3406.

NewEdge Advisors first reported a position in OGN in Q4 2021 and has held it in 16 quarters since. The position peaked at $628K in Q4 2021. 627 funds tracked by Wall St. Rank hold OGN as of Q2 2026.

  • NewEdge Advisors held 1,249 shares of Organon & Co worth $16.9K as of Q2 2026.
  • NewEdge Advisors sold 1,033 Organon & Co shares in Q2 2026, an estimated $12.4K.
  • Organon & Co made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #3406 holding.
  • NewEdge Advisors first reported a position in Organon & Co in Q4 2021 and has held it in 16 quarters since.
  • NewEdge Advisors's Organon & Co position peaked at $628K in Q4 2021.
  • 627 funds tracked by Wall St. Rank held Organon & Co as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.